HEPA Stock Overview
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Hepion Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.48 |
| 52 Week High | US$23.85 |
| 52 Week Low | US$5.20 |
| Beta | 1.63 |
| 1 Month Change | -29.46% |
| 3 Month Change | -45.39% |
| 1 Year Change | -38.43% |
| 3 Year Change | -77.85% |
| 5 Year Change | -99.56% |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Apr 25
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Oct 27Hepion Pharma rises as company begins NASH treatment trial
Aug 31Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?
Jul 04Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH
Feb 17Hepion Pharmaceuticals: Facing The Momentous Year 2022
Jan 21Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug
Sep 21Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth
Sep 14Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race
Sep 08Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)
May 26What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?
Feb 18Hepion Pharma cleared to advance final dosing cohort in NASH trial
Dec 29Hepion Pharma to begin CRV431 testing in COVID-19 patients
Dec 22Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study
Dec 10Hepion Pharma prices equity offering at $1.50
Nov 25Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow
Oct 31Shareholder Returns
| HEPA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -18.6% | -1.2% | 1.0% |
| 1Y | -38.4% | -2.3% | -0.2% |
Return vs Industry: HEPA underperformed the US Pharmaceuticals industry which returned -4.1% over the past year.
Return vs Market: HEPA underperformed the US Market which returned -0.1% over the past year.
Price Volatility
| HEPA volatility | |
|---|---|
| HEPA Average Weekly Movement | 37.5% |
| Pharmaceuticals Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HEPA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 37% a week.
Volatility Over Time: HEPA's weekly volatility has increased from 23% to 37% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 25 | Bob Foster | https://www.hepionpharma.com |
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.
Hepion Pharmaceuticals, Inc. Fundamentals Summary
| HEPA fundamental statistics | |
|---|---|
| Market Cap | US$36.59m |
| Earnings (TTM) | -US$51.67m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs HEPA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HEPA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$51.67m |
| Earnings | -US$51.67m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.56 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did HEPA perform over the long term?
See historical performance and comparison